Skip to main content
Premium Trial:

Request an Annual Quote

Myconostica Raises $7.7M in Series C Financing

NEW YORK (GenomeWeb News) – Myconostica, a molecular diagnostics spinout from the University of Manchester in the UK, has raised £3.9 million ($7.7 million) at £40 ($79) per share in a Series C financing.
The firm previously raised £500,000 in the Series C round, which included investments from London-based Amphion Innovations, Boston-based Nexus Medical Partners, and France-based Innoven Partenaires, as well as several other unnamed UK and international investors. Following this round of funding, Amphion owns 25 percent of Myconostica, which is currently valued at £12 million, according to Amphion.
Myconostica is developing real-time molecular diagnostic tests for a variety of life-threatening fungal infections. The funds raised in the most recent round of financing will be used to support commercialization of the firm’s first products: FXG RESP (ASP+), which is a test for aspergillus and pneumocystis, and an associated fungal extraction system called MycXtra.
These products are in the final stages of CE marking in Europe, Amphion said, and the firm expects a US launch in the fourth quarter of this year.
In connection with the funding, Myconostica has named Edwin Snape, co-founder and head of the healthcare practice at Nexus Medical Partners, to its board of directors.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.